AlphaMark Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-740
Closed 639
2019
Q4
$0 Sell
740
-25
-3% ﹤0.01% 529
2019
Q3
$0 Hold
765
﹤0.01% 534
2019
Q2
$0 Hold
765
﹤0.01% 543
2019
Q1
$4K Hold
765
﹤0.01% 432
2018
Q4
$3K Hold
765
﹤0.01% 428
2018
Q3
$8K Hold
765
﹤0.01% 376
2018
Q2
$6K Buy
765
+25
+3% +$174 ﹤0.01% 429
2018
Q1
$4K Hold
740
﹤0.01% 444
2017
Q4
$7K Hold
740
﹤0.01% 390
2017
Q3
$7K Hold
740
﹤0.01% 379
2017
Q2
$9K Hold
740
﹤0.01% 362
2017
Q1
$8K Hold
740
﹤0.01% 359
2016
Q4
$7K Hold
740
﹤0.01% 354
2016
Q3
$9K Buy
+740
New +$11.2K ﹤0.01% 254

AlphaMark Advisors's INSY Position: Q1 2020 in Review

AlphaMark Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q1 2020, closing a stake of 740 shares.

AlphaMark Advisors first reported a position in INSY in Q3 2016 and held it in 14 quarters. The position peaked at $9K in Q2 2017. 1 fund tracked by Wall St. Rank holds INSY as of Q1 2020.

  • AlphaMark Advisors reported no remaining Insys Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • AlphaMark Advisors sold 740 Insys Therapeutics, Inc. shares in Q1 2020.
  • AlphaMark Advisors first reported a position in Insys Therapeutics, Inc. in Q3 2016 and held it in 14 quarters.
  • AlphaMark Advisors's Insys Therapeutics, Inc. position peaked at $9K in Q2 2017.
  • 1 fund tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2020.

Based on AlphaMark Advisors's 13F filing for Q1 2020, filed 24 Apr 2020.